Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

A First-in-Human, Phase 1/2, Dose-ascending, Multicenter, Masked, Randomized, Vehicle-controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AGN-241622 in Healthy Participants and Participants With Presbyopia (Stage 1 and Stage 2) and Efficacy in Participants With Presbyopia (Stage 2)

The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants

Inclusion Criteria:

• Age 40 to 65 at the time of study participation.
• Be a nonsmoker and nonuser of nicotine-containing products within the previous 1 year.
• Be able and willing to follow study instructions and complete all required study visits in the opinion of the study doctor.

Exclusion Criteria:

• History of alcohol or substance abuse within the 5 years prior to study participation.
• Enrollment in another investigational drug or device study within 30 days of study participation.
• Women who are pregnant, nursing, or planning a pregnancy during the study.